Blood-based biomarkers hold great promise to revolutionize the diagnostic and prognostic
work-up of Alzheimer's disease (AD) in clinical practice. This is very timely, considering the …

Timely detection of the pathophysiological changes and cognitive impairment caused by
Alzheimer's disease (AD) is increasingly pressing because of the advent of biomarker …

With the emergence of Alzheimer's disease (AD) disease-modifying therapies, identifying
patients who could benefit from these treatments becomes critical. In this study, we …

The advent of proteomics offers an unprecedented opportunity to predict dementia onset.
We examined this in data from 52,645 adults without dementia in the UK Biobank, with 1,417 …

Longitudinal multimodal biomarker studies reveal that the continuum of Alzheimer's disease
(AD) includes a long latent phase, referred to as preclinical AD, which precedes the onset of …

Background Recently developed blood markers for Alzheimer's disease (AD) detection have
high accuracy but usually require ultra-sensitive analytic tools not commonly available in …

Background Novel phosphorylated-tau (p-tau) blood biomarkers (eg, p-tau181, p-tau217 or
p-tau231), are highly specific for Alzheimer's disease (AD), and can track amyloid-β (Aβ) and …

Disease staging, whereby the spatial extent and load of brain pathology are used to
estimate the severity of Alzheimer disease (AD), is pivotal to the gold-standard …

Background and objective Phosphorylated tau (p-tau) 217 has recently received attention
because it seems more reliable than other p-tau variants for identifying Alzheimer's disease …

Biological staging of individuals with Alzheimer's disease (AD) may improve diagnostic and
prognostic workup of dementia in clinical practice and the design of clinical trials. In this …